Clinical Epigenetics, the official journal of the Clinical Epigenetics Society, is an open access, peer-reviewed journal that encompasses all aspects of epigenetic principles and mechanisms, as well as reports on defects of epigenetic regulation, in relation to human disease, diagnosis and therapy. Epigenetic research in disease model organisms is particularly welcome.
- Ulrich Mahlknecht, St Lukas Clinic, Solingen
Ulrich Mahlknecht is currently a Professor of medicine at the University of Heidelberg, and Head of the Department of Hematology/Oncology at St. Lukas Clinic in Solingen, Germany.
His research focuses on novel targeted immunological and epigenetic concepts in the treatment of solid tumors and hematological malignancies.
The "Clinical Epigenetics Society" (CLEPSO) is a non-profit organization founded at Saarland University.
The society has five main objectives:
- Promotion and support of scientific research projects and initiatives within the field of clinical epigenetics.
- Promotion of the scientific exchange amongst its members.
- Encouragement and support of relations to national and international societies within the area of clinical and translational research.
- Development of an international research and scientific network within the field of clinical epigenetics.
- Providing a forum for encouraging discussions and contributions to the advancement of clinical epigenetics, through the Clinical Epigenetics journal, Blogs, scientific symposia, meetings, and newsletters.
From the blog
- 18 November 2013
- Constructive complexity; molecular structures suggest new possibilities for HDAC inhibitor therapy
- 12 November 2013
- Epigenomics alive and well in Japan
- 11 October 2013
- Genetic mosaicism: does epigenetics have anything to do with it?
In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.
Volume 5 Suppl 1 (19 August 2013)
Birmingham, UK. 16 May 2013